Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS ...

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012 ...

Core Viewpoint - Keros Therapeutics has voluntarily halted dosing in certain treatment arms of the TROPOS trial due to safety concerns related to adverse events observed in patients with pulmonary arterial hypertension [1][2] Group 1: Company Actions - The company announced a halt in dosing for the 3.0 mg/kg and 4.5 mg/kg treatment arms of the TROPOS trial while continuing with the 1.5 mg/kg arm after a safety review [1][2] - Keros is collaborating with the FDA and other regulatory authorities to address the safety concerns and has notified investigators about the decision [2] - The company expects to present topline data from all treatment arms in the TROPOS trial in the second quarter of 2025 [2] Group 2: Trial Information - The TROPOS trial is a Phase 2 clinical trial evaluating the efficacy of cibotercept in patients with pulmonary arterial hypertension [4] - The primary objective of the trial is to assess the effect of cibotercept on pulmonary hemodynamics compared to placebo [4] - The trial is fully enrolled, and the independent Data Monitoring Committee conducted a risk and benefit assessment prior to the dosing halt [2] Group 3: Product Information - Cibotercept is designed to inhibit TGF-β signaling, which is linked to smooth muscle hypertrophy and fibrosis, potentially treating conditions like pulmonary arterial hypertension [5] - The drug aims to enhance BMP signaling pathways, which are often reduced in patients with certain cardiovascular disorders [5]

Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results LEXINGTON, Mass., November 6, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a ...

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2024. “This continues to be ...

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...

LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare ...

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all progra ...